Trials / Recruiting
RecruitingNCT06185569
FREDO-ODX Study: FREnch Data on Outcomes in HR+/HER2- Early Breast Cancer Patients With oncotypeDX Recurrence Score-guided Therapy
FREnch Data on Outcomes in HR+/HER2- Early Breast Cancer Patients With oncotypeDX Recurrence Score-guided Therapy
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 4,500 (estimated)
- Sponsor
- Centre Hospitalier Universitaire de Besancon · Academic / Other
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The aim of this study is to assess the clinical outcomes in real-life setting of early breast cancer RH+ HER2- patients with systemic therapy guided by Oncotype DX (ODX) Breast Recurrence Score®.
Conditions
Timeline
- Start date
- 2023-10-15
- Primary completion
- 2028-09-01
- Completion
- 2029-03-01
- First posted
- 2023-12-29
- Last updated
- 2023-12-29
Locations
5 sites across 1 country: France
Source: ClinicalTrials.gov record NCT06185569. Inclusion in this directory is not an endorsement.